4-way competition in NOAC market, well-played by Eliquis and Lixiana
While 4 products are settled in the novel oral anticoagulant(NOAC) market, competition is expected to get fiercer.
Bayer’s Xarelto(rivaroxaban) gained the summit of the market; BMS’s Eliquis(apixaban) and a new strong competitor Daiichi Sankyo’s Lixiana(edoxaban) continued a growth; Boehringer I...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.